The decision to use dabrafenib and trametinib was inspired by the molecular similarity between the BRAF A598_T599insI mutation observed in this pediatric patient and the case report of a 74‐year‐old patient with metastatic melanoma harboring a similar mutation BRAF A598_T599insV, for whom targeted therapy achieved a partial response lasting 5 months [8]. Here, BRAF is linked to metastatic melanoma.